References

All internet references were checked during April 2012

1. QAAMS. Quality Assurance for Aboriginal and Torres Strait Medical Services.
2. iCCnet. Integrated Cardiovascula Clinical Network.
3. Rosselli D. The Budda and the search for evidence. MJA 2002; 176:404.
4. Ehrmeyer SS. Regulatory issues regarding point-of-care testing. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010. Chapter 19, page 237.
5. Price CP, St John A, Kricka LJ. Putting point-of-care testing into context: Moving beyond innovation to adoption. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010. Chapter 1, page 1.
6. ISO 22870:2006. Point-of-care testing (POCT) – Requirements for quality and competence.
7. O’Kelly RA, Brady JJ, Byrne E, Hooley K, Mulligan C, Mulready K, etal. A survey of point of care testing in Irish hospitals. Ir J Med Sci 2011;180:237-240.
8. Open Clinical. Clinical practice guidelines.
9. National Pathology Accreditation Advisory Council (NPAAC).
10. Standards Australia. What is a standard ?
11. National Pathology Accreditation Advisory Council (NPAAC).
12. National Pathology Accreditation Advisory Council (NPAAC) publications.
13. Australian Government, Department of Health and Ageing. Interim standards for point of care testing in general practice trial (incorporating POCT trial guidelines).
14. Australian Government, Department of Health and Ageing. Point of care testing in general practice trial.
15. Medical Services Advisory Committee (MSAC).
16. Medical Services Advisory Committee (MSAC). Guidelines for the assessment of diagnostic technologies - May 2007.
17. Medical Services Advisory Committee (MSAC). Funding for new medical technologies and procedures: application and assessment guidelines - September 2005.
18. AACB. Point of care testing implementation guide, 2008.
19. AACB. Guidelines for conducting quality control and quality assurance for POCT, 2010.
20. RCPA. Position statement. Point of care testing.
21. Australian Government, Department of Health and Ageing. Point of care testing in general practice trial. Chapter 14, page 343, chapter summary and conclusions.
22. Shephard M, etal. Design, implementation and results of the quality control program for the Australian government’s point of care testing in general practice trial. Ann Clin Biochem 2009; 46: 413.
23. Shephard MDS. Influence of geography on the performance of quality control testing in the Australian government’s point of care testing in general practice trial. Clin Biochem 2009; 42: 1325.
24. White GH and Farrance I. Uncertainty of measurement in quantitative medical testing – A laboratory implementation guide. Clin Biochem Rev 2004; 25 supplement (ii): S1.
25. Fraser CG. General strategies to set quality specifications for reliability performance characteristics. Scand J Clin Lab Invest 1999; 59: 487.
26. Fraser CG. Optimal analytical performance for point of care testing. Clin Chim Acta 2001; 307: 37.
27. Fraser CG and Scott MG. Chapter 12, Analytical performance requirements for point-of-care testing: Glucose as an example. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010.
28. Price CP and St John A. Chapter 14, Outcomes in point-of-care testing: Research and validation. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010.
29. FDA public meeting: Blood glucose meters - March, 2010.
30. Bierig JR. Malpractice issues in the use of blood glucose meters.
31. Ministry of Health and Long-Term Care, Ontario, Canada. Point of care testing policy and guidelines for hospitals with a licensed laboratory.
32. Ontario Medical Association. Guidelines: Quality assurance program for INR testing with point of care devices in Ontario.
33. Ministry of Health and Long-Term Care, Ontario, Canada. Policies, procedures and quality assurance for point of care HIV testing in Ontario.
34. Cancer care Ontario, program in evidence –based care. Guaiac fecal occult blood testing laboratory standards.
35. College of Physicians and Surgeons of Alberta (Canada). Unaccredited point of care testing guidelines for physicians.
36. Agence d’evaluation des technologies et des modes d’intervention en santé (AETMIS). Point of care testing in the private sector (report summary in English).
37. Agence d’evaluation des technologies et des modes d’intervention en santé (AETMIS). Point of care testing in the private sector (full report in French).
38. Pernet P, etal. Point-of-care testing management protocol using ISO 22870 guidelines and French requirements. Clin Biochem 2009; 42: 324.
39. Editorial announcement. Directive: the Federal Medical Council for quality assurance of medical laboratory tests. Dtsch Arztebi 2008; 105(7): A-341.
40. Joint committee for POCT in primary care and community care. Guidelines for safe and effective management and use of point of care testing in primary and community care.
41. Joint committee for POCT. Guidelines for safe and effective management and use of point of care testing.
42. Soto AB, etal. Proposed guidelines for point-of-care testing in Spain. Point of Care 2009; 8: 53.
43. SEQC, Sociedad Española de Bioquímica Clínica y Patología Molecular. Guía para la implantación de pruebas de laboratorio en el lugar de asistencia al paciente.
44. United Kingdom Department of Health. Medical and healthcare products regulatory agency (MHRA). Management and use of IVD point of care test devices, 2010.
45. NHS Fife. Point of care testing devices (policy).
46. Northern Health and Social Care Trust. Point of care testing policy, 2009.
47. Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust. Point of care policy, 2008.
48. Ashford and St Peter’s Hospitals NHS Trust. Point of care testing policy, 2009.
49. Craigavon area Hospital Group Trust. Point of care testing (POCT) policy, 2008.
50. Conway and Denbighshire NDS Trust. Near patient testing / point of care testing policy, 2008.
51. Clinical pathology accreditation (UK). Additional standards for point-of-care testing (POCT) facilities.
52. NHS. Point of care testing in critical care, 2004.
53. Association of Clinical Biochemists. Guidelines for implementation of near- patient testing, 1993.
54. Royal College of Pathologists (RCPath). Guidelines for point of care testing.
55. British Committee for Standards in Haematology. Guidelines for point of care testing: Haematology. BJH 2008; 142: 904.
56. Welsh Scientific Advisory Committee. Point of care testing: The use of diagnostic equipment and procedures outside the diagnostic laboratory.
57. Northern Ireland. Department of Health, Social Services and Public Safety. Recommendations for the future of pathology services in Northern Ireland, December 2007.
58. Medical Devices Agency, Health Estates. Management and use of IVD point of care test devices. DB(NI)2002/03, June 2002.
59. British Medical Association. Near-patient testing. National Enhanced Service - provision of near-patient testing (updated December 2003).
60. British Medical Association. Anti-coagulation monitoring. National enhanced service - anti-coagulation monitoring (revised November 2003).
61. National Academy of Clinical Biochemistry (NACB). Laboratory medicine practice guidelines: Evidence-based practice for point-of-care testing. 2006.
62. Centers for Disease Control and Prevention (CDC). Good laboratory practices for waived testing sites.
63. American Academy of Family Physicians. Recommended curriculum guidelines for family medicine residents. Office Laboratory Medicine, 2008.
64. College of American Pathologists. Commission on Laboratory Accreditation, laboratory accreditation program. Point-of-care-testing checklist, 2009.
65. The Joint Commission. Standards for laboratory accreditation.
66. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn’t. Br Med J 1996; 312: 71.
67. Price CP. Evidence-based laboratory medicine: Supporting decision making. Clin Chem 2000; 46: 1041.
68. Price CP. Application of the principles of evidence-based medicine to laboratory medicine. Clin Chim Acta 2003; 333: 147.
69. Hawkins RC. The evidence based medicine approach to diagnostic testing: practicalities and limitations. Clin Biochem Revs 2005; 26: 7.
70. Oosterhuis WP, etal. Evidence-based guidelines in laboratory medicine: Principles and methods. Clin Chem 2004; 50: 806.
71. Christenson RH. Evidence based laboratory medicine – a guide for critical evaluation of in vitro laboratory testing. Ann Clin Biochem 2007; 44: 111.
72. Christenson RH, Snyder SR, Shaw CS, Derzon JH, Black RS, Mass D, etal. Laboratory medicine best practices: Systematic evidence review and evaluation methods for quality improvement. Clin Chem 2011;57:816-825.
73. World Health Organisation (WHO) and International Diabetes Federation (IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO / IDF consultation. 2006.
74. Coleman PG, etal. Position statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. New classification and criteria for diagnosis of diabetes mellitus. MJA 1999; 170: 375.
75. National Academy of Clinical Biochemistry (NACB). Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. 2011. Edited by Sacks DB. Or Sacks DB, Arnold M, Bakris GL, Burns DE, Horvath AR, Kirkman MS, etal. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (special report). Clin Chem 2011;57:e1-e47.
76. Sacks DB, Arnold M, Bakris GL, Burns DE, Horvath AR, Kirkman MS, etal. Executive summary: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011;57:793-798.
77. Al-Ansary L, Farmer A, Hirst J, Roberts N, Glasziou P, Perera R and Price CP. Point-of-care testing for HbA1c in the management of diabetes: A systematic review and metaanalysis. Clin Chem 2011;57:568-576.
78. Sacks DB. Presentation to the US FDA enquiry into the performance of blood glucose meters, March 2010.
79. Westgard JO. FDA hears concerns on blood glucose meters.
80. Price CP and Kricka LJ. Improving healthcare accessibility through point-of-care technologies. Clin Chem 2007; 53: 1655.
81. Shephard MDS and Gill JP. The National QAAMS program – A practical example of POCT working in the community. Clin Biochem Rev 2010; 31: 95.
82. Francis AJ and Martin CL. A practical example of POCT working in the community. Clin Biochem Rev 2010; 31: 93.
83. Tideman P, Simpson P and Tirimacco R. Integrating POCT into clinical care. Clin Biochem Rev 2010; 31: 99.
84. Bubner TK, etal. Effectiveness of point-of-care testing for therapeutic control of chronic conditions: results from the POCT in general practice trial. MJA 2009; 190: 624.
85. St John A. The evidence to support point-of-care testing. Clin Biochem Rev 2010; 31: 111.
86. Price CP and St John A. Outcomes in point-of-care testing: Research and validation. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010. Chapter 14, page 171.
87. Fraser CG. Quality specifications. In: Biological variation: From principles to practice. Fraser CG, AACC Press, 2001. Chapter2, page 29.
88. NPAAC. Requirements for the estimation of measurement uncertainty, 2007.
89. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010; 56: 714.
90. Boyd JC and Burns DE. Quality specifications for glucose meters: Assessment by simulation modeling of errors in insulin dose. Clin Chem 2001; 47: 209.
91. Shephard MDS. Analytical goals for point-of-care used for diabetes management in Australian health care settings outside the laboratory. POC 2006; 5: 177.
92. Shephard MDS and Gill JP. Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA2000 in Australian aboriginal community controlled health services. Clin Biochem Rev 2003; 24: 123.
93. Shephard MDS and Gill JP. The analytical quality of point-of-care testing in the QAAMS model for diabetes management in Australian Aboriginal Medical Services. Clin Biochem Rev 2006; 27: 185.
94. Shephard MDS, etal. Design, implementation and results of the quality control program for the Australian government’s point-of-care testing in general practice trial. Ann Clin Biochem 2009; 46: 413.
95. Gill JP and Shephard MDS. The conduct of quality control and quality assurance testing for POCT outside the laboratory. Clin Biochem Rev 2010; 31: 85.
96. Martin CL. Quality issues in point-of-care testing. Clin Biochem Rev 2008; 29 suppl (i): S79.
97. Tirimacco R, Tideman P and Simpson P. Design, implementation and outcomes for point-of-care pathological testing in a cardiac clinic network. Point of Care 2009; 8: 56.
98. Sacks DB, etal. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436.
99. Trence DL, etal. The rationale and management of hyperglycaemia for in-patients with cardiovascular disease: Time for change. J Clin Endocrinol Metab 2003; 88: 2430.
100. Price CP. Glucose monitoring and patient safety. Point of Care 2008; 7: 253.
101. Freckmann G, etal. System accuracy evaluation of 27 blood glucose monitoring systems according to DIN EN ISO 15197. Diabetes Technology and Therapeutics 2010; 12: 221.
102. Burns DE and Boyd JC. Few point-of-care haemoglobin A1c assay methods meet clinical needs (editorial). Clin Chem 2010; 56: 4.
103. Lenters-Westra E and Slingerland RJ. Six of eight haemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010; 56: 44.
104. Petersen PH, etal. Consequences of bias and imprecision in measurement of glucose and HbA1c for diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest 2005; 65 (suppl 240): 51.
105. Wittels P, etal. Chapter15, Reimbursement of point-of-care tests. In: Point-of- care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010.
106. Tirimacco R. Evolution of point-of-care testing in Australia. Clin Biochem Rev 2010; 31: 75.
107. ISO 15189 – 2007 (AS 4633 – 2007). Medical laboratories – Particular requirements for quality and competence.
108. Mighani RA. Current status of point-of-care testing in clinical toxicology. Point of Care 2008; 7: 266.
109. Watson ID, etal. Chapter 7, Drugs and ethanol. In: National Academy of Clinical Biochemistry (NACB). Laboratory medicine practice guidelines: Evidence-based practice for point-of-care testing. 2006.
110. Valdes R, etal. Chapter 41, Point-of-care testing and the optimization of pharmacotherapeutics. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010.
111. Junker R, etal. Point-of-care testing in hospitals and primary care. Dtsch Arzteb Int 2010; 107: 561.
112. Blattner K, Nixon G, Dovey S, Jaye C, Wigglesworth J. Changes in clinical practice and patient disposition following the introduction of point-of-care testing in a rural hospital. Health Policy 2010;96:7-12.
113. Lord Carter of Coles (chairman). Report of the second phase of the review of NHS pathology services in England. 2008.
114. Lord Carter of Coles (chairman). Report of the second phase of the review of NHS pathology services in England. 2008. Recommendation 12, page 11. Recommendation 14, page 12.
115. Medicines and Healthcare Products Regulatory Agency (MHRA).
116. Northern Ireland. Department of Health, Social Services and Public Safety. The future of pathology services in Northern Ireland, November 2006.
117. Northern Ireland. Department of Health, Social Services and Public Safety. The future of pathology services in Northern Ireland, summary of responses to public consultation, December 2007.
118. Welsh Scientific Advisory Committee (WSAC)
119. Burnett D. Accreditation and point-of-care testing. Ann Clin Biochem 2000; 37: 241.
120. Thomas MA. Quality assurance and accreditation in point-of-care testing. POC 2008; 7: 227.
121. Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. 263a PL100-578 (1988).
122. Requirements for Certificate of Waiver.
123. Centers for Medicare and Medicade Services.
124. Clinical Laboratory Improvement Advisory Committee (CLIAC). Summary report of meeting, “Recognising 20 years of CLIA”. February 2008.
125. CDC information. Clinical Laboratory Improvement Advisory Committee (CLIAC). Summary report of meeting
126. COLA, laboratory accreditation.
127. Sautter RL and Lipford EH. Point-of-care-testing: Guidelines and challenges. North Carolina Medical Journal 2007;68: 132.
128. Clinical Laboratory Improvement Amendments - Currently waived analytes.
129. Office of the Director and CEO, American Academy of Family Medicine. Personal communication.
130. Institute of Medicine. To err is human – Building a better health system, November 1999.
131. Okorodudu AO. Optimizing accuracy and precision for point-of-care testing. POC 2012;11:26-29.
132. Tirimacco R. Design, implementation and outcomes for POCT: cost implications. POC 2008; 7 (3): 128.
133. Plebani M. Does POCT reduce the risk of error in laboratory testing ? Clin Chim Acta 2009; 404: 59.
134. Nichols JH. Medical errors – Can we achieve an error-free system ? POCT 2005; 4(4): 139.
135. Thompson ND and Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diab Sci and Technol 2009; 3(2): 283.
136. Sharp GH, etal. Physician office testing – The importance of ongoing monitoring. POC 2003; 2(3): 179.
137. Bonini P, etal. Errors in laboratory medicine. Clin Chem 2002; 48: 691.
138. O’Kane MJ, McManus P, McGowan N, Lynch PLM. Quality error rates in point- of-care testing. Clin Chem 2011;57:1267-1271.
139. CMS internet site. Certificate of waiver project.
140. CMS. CMS certificate of waiver and provider performed microscopy procedures pilot project.
141. Meier FA and Jones BA. Point-of-care testing error – Sources and amplifiers, taxonomy, prevention strategies, and detection monitors. Arch Pathol Lab Med 2005; 129: 1262.
142. Kendall J, etal. Point-of-care testing: randomized controlled trial of clinical outcome. BMJ 1998; 316: 1052.
143. Blattner K, etal. Changes in clinical practice and patient disposition following the introduction of point-of-care testing in a rural hospital. Health Policy 2010; 96: 7.
144. Hobbs FDR, etal. A review of near patient testing in primary care. Health Technology Assessment 1997; 1(5).
145. Grieve R, etal. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technology Assessment 1999; 3(15).
146. Collinson PO, etal. A prospective randomized controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004; 41: 397.
147. Ryan RJ, etal. A multicenter randomized controlled trial comprising central laboratory and point-of-care cardiac marker testing strategies: the disposition impacted by serial point-of-care markers in acute coronary syndromes (DISPO- ACS) trial. Ann Emerg Med 2009; 53: 321.
148. Fitzmaurice DA, etal. A randomized controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002; 55: 845.
149. Fitzmaurice DA, etal. Self management of oral anticoagulation: randomized trial. BMJ 2005; 331: 1057.
150. Parry D, etal. Anticoagulation management in primary care: a trial-based economic evaluation. Br J Haematol 2000; 111: 530.
151. Wilson SJ, etal. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Canadian Med Assoc J 2003; 169: 293.
152. Khunti K, etal. Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. Br J Gen Practice 2006; 56: 511.
153. National Pathology Accreditation Advisory Council (NPAAC). Requirements for participation in external quality assessment.. 2009.
154. Gill JP and Watkinson L. Chapter 18, Quality control and quality assurance in point-of-care testing. In: Point-of-care testing. Needs, opportunity and innovation. Edited by Price CP, St John A and Kricka LJ. AACC Press 2010.
155. Miller WG, Jones GRD, Horowitz GL, Weykamp C. Proficiency testing / external quality assessment: Current challenges and future directions. Clin Chem 2011;57:1670-1680.
156. Levey S and Jennings ER. The use of control charts in the clinical laboratory. Am J Clin Pathol 1950; 20: 1059.
157. National Pathology Accreditation Advisory Council (NPAAC). Requirements forpathology laboratories. 2007.
158. Fremner E, etal. Total quality assurance in a distributed point-of-care testing laboratory organization in primary health care. POC 2004; 3:99.
159. Australian Government, Department of Health and Ageing. Point of care testing in general practice trial. Chapter 14; Item 14.2, Quality management system, page 344.